HealthcareServices

Biomarker Clinical Phase Outsourcing Services Market Forecast 2026: Where the Industry Is Headed

February 20, 2026February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biomarker clinical phase outsourcing services market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Biomarker Clinical Phase Outsourcing Services Market between 2026 and 2030?

The biomarker clinical phase outsourcing services market has experienced substantial growth in recent years. It is projected to expand from $11.91 billion in 2025 to $14.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.7%. The market’s past development can be attributed to the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the progression of biomarker-driven drug development, the expansion of translational research programs, and enhanced collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market is projected to experience rapid expansion over the upcoming years. This market is anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This expansion during the projected timeframe is attributable to several factors, including a heightened demand for personalized medicine trials, the growing adoption of AI-driven biomarker analytics, the enlargement of multi-biomarker clinical studies, increased investments in precision oncology, and a stronger regulatory focus on biomarker validation. Key trends characterizing this period involve the rising outsourcing of biomarker clinical trial operations, an increase in the application of predictive and prognostic biomarkers, the expanding integration of omics-based biomarker analysis, the further development of companion diagnostics, and a sharpened emphasis on precision medicine trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Biomarker Clinical Phase Outsourcing Services Market?

The rise in clinical trials is projected to fuel the expansion of the biomarker clinical phase outsourcing services market. Clinical trials involve research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The escalation in clinical trials is supported by advancements in medical research, an increasing prevalence of chronic diseases, enhanced funding from both governmental and private entities, and a growing demand for innovative treatments and therapies. Outsourcing providers often possess specialized knowledge and expertise in biomarker discovery, validation, and analysis, which can improve the quality and reliability of biomarker data collected during the trial. For instance, in November 2025, the National Library of Medicine, a US-based biomedical library, reported that ClinicalTrials.gov currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Therefore, the increase in clinical trials will propel the growth of the biomarker clinical phase outsourcing services market.

How Is The Biomarker Clinical Phase Outsourcing Services Market Organized Into Various Segments?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

How Are New Market Trends Shaping The Landscape Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in the biomarker clinical phase outsourcing services are concentrating on enhancements with high-throughput flow cytometry and ELISpot testing to achieve a competitive advantage in the market. High-throughput flow cytometry and ELISpot testing are employed for biomarker analysis, delivering quick and accurate evaluation of immune responses and cellular markers. For instance, in May 2024, KCAS Bio, a U.S.-based bioanalytical CRO providing GLP/GCP-compliant biomarker and immune-monitoring services, established a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO proficient in ELISpot and flow cytometry assays. Via this partnership, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, enabling clients to utilize high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This collaboration strengthens KCAS’s capabilities in biomarker development and immune-monitoring by ensuring rapid, precise assessment of cellular biomarkers in clinical trials, thus allowing clients to produce high-quality data that supports regulatory submissions and expedites drug development.

Who Are The Primary Competitors In The Global Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biomarker Clinical Phase Outsourcing Services Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biomarker Discovery Outsourcing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795